Dr.  

Kim A. Papp

, Waterloo - Canada

Presentations

Adverse events from biologic therapy 12 October 2019 15:40 - 16:00
Long-term Efficacy and Safety of Continuous Q12W Risankizumab: Results from the Open-Label Extension LIMMitless 10 October 2019 08:30 - 08:40
Analysis of Patients With Moderate Psoriasis in "Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for the Treatment of Psoriasis" (OBSERVE-5) 09 October 2019 00:00 - 00:00
Patient-Related Outcomes in the "Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for the Treatment of Psoriasis" (OBSERVE-5) Population 09 October 2019 00:00 - 00:00

Abstracts

Analysis of Patients With Moderate Psoriasis in "Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for the Treatment of Psoriasis" (OBSERVE-5) Psoriasis More
Patient-Related Outcomes in the "Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for the Treatment of Psoriasis" (OBSERVE-5) Population Psoriasis More
Efficacy and Safety of Risankizumab in Patients With Active Psoriatic Arthritis Over 24 Weeks: Clinical and Biomarker Results From a Phase 2 Trial Biologics, Immunotherapy, Molecularly Targeted Therapy More